This is the authors' abstract. We don't add key points for this paper.
IgA nephropathy (IgAN) is one of the most common glomerular diseases worldwide and carries a high disease burden with 30%-40% of patients developing kidney failure.1 Given its heterogeneous course, a combination of clinical, laboratory, and histopathologic parameters are used to identify patients at risk of poor outcomes.2 Multiple trials have explored the use of corticosteroids and other immunosuppressive medications in high-risk IgAN. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial in 2015 compared immunosuppressive therapy (with cyclophosphamide, azathioprine, and/or oral prednisolone) added to a background of optimized renin angiotensin system blockade, compared to supportive care alone.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chellappan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: